Hainan Poly Pharm News

Hainan Poly Pharm: An indicative announcement on the suspension of trading of Puli Bonds and the suspension of share conversion

12:00 ET

Hainan Poly Pharm: Announcement on the inability to disclose the 2023 Annual Report and the 2024 First Quarter Report and the suspension of trading of company stocks and convertible corporate bonds within the statutory period

12:00 ET

Hainan Poly Pharm: An indicative announcement on the risk of the company's shares being subject to delisting risk

12:00 ET

Hainan Poly Pharm: An indicative notice on the risk of not being able to disclose the 2023 Annual Report and the 2024 First Quarter Report within the statutory period

Apr 29 11:17 ET

Hainan Poly Pharm: An indicative announcement on Pulley's bond conversion that is expected to trigger a downward revision of the conversion price

Apr 26 07:35 ET

Hainan Poly Pharm: An indicative announcement on the deferred disclosure of the 2023 Annual Report

Apr 26 06:13 ET

Puli Pharmaceuticals: Announcement on oseltamivir phosphate capsules obtaining marketing approval from the State Drug Administration

Apr 23 06:09 ET

Puli Pharmaceuticals: Announcement on the Company's Response to the Letter of Concern on the Shenzhen Stock Exchange

Apr 19 09:46 ET

Puli Pharmaceuticals: Announcement on receipt of a supervisory letter from an independent director

Apr 19 09:45 ET

Prednisolone Pharmaceuticals: Announcement on the marketing approval of voriconazole injections from the Norwegian Medicines Agency

Apr 17 06:12 ET

Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for voriconazole injections from the Finnish National Drug Administration

Apr 8 05:48 ET

Prednisolone Pharmaceuticals: Announcement on obtaining marketing approval for voriconazole injections from the Swedish Medicines Agency

Apr 7 12:00 ET

Puri Pharmaceuticals: Announcement on Daptomycin for injections obtained marketing approval from the German Federal Institute for Drugs and Medical Devices (BfArM)

Apr 3 06:20 ET

Puli Pharmaceuticals: Announcement on the change of signed accountant

Apr 3 06:18 ET

Puli Pharmaceuticals: Announcement on the conversion of convertible corporate bonds to shares in the first quarter of 2024

Apr 1 06:36 ET

Puri Pharmaceuticals: Notice on submission of 8- (2-hydroxybenzamide) sodium caprylate (SNAC) pharmaceutical excipients to the U.S. DMF

Mar 14 06:32 ET

Puri Pharmaceuticals: Announcement on obtaining marketing approval for injectable pantoprazole sodium from the Department of Pharmacy of the Ministry of Health of Israel

Mar 5 02:58 ET

Puri Pharmaceuticals: Announcement on obtaining marketing approval for sodium nitrate injections in Germany

Feb 6 06:27 ET

Puli Pharmaceuticals: Announcement on 2024 Interest Payments on Convertible Corporate Bonds

Feb 2 05:43 ET

Puli Pharmaceuticals: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders

Jan 26 04:52 ET